A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ReNeuron Group
Ticker: RENE Exchange: AIM

ReNeuron Group plc is an AIM listed biotechnology company developing allogeneic cell therapies. Its first product is the CTX neural stem cell therapy for the treatment of chronic stroke disability with results expected in early 2020. Its second product is human retinal progenitor cells (hRPCs) which are being studied for RP in a Phase I/IIa study.

ReNeuron Group 09 Dec 2019

Encouragement from interims

ReNeuron Group plc is an AIM listed biotechnology company developing allogeneic cell therapies. Its...

Read more
ReNeuron Group 19 Nov 2019

Now the dust has settled

ReNeuron Group is an AIM listed biotechnology company developing allogeneic cell therapies. Their...

Read more
  • 1 of 1 pages

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates
Equity Development
Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.
Equity Development Limited 2nd Floor, Park House, 16-18 Finsbury Circus, London, EC2M 7EB
© 2024 Equity Development Limited. Regulated by the FCA.
Website design & development by Breckenridge